Table 5.

Risk of bias table for biochemical liver function tests

Trial ID	Number of tests	Days tested	Days reported	Days tested adequate?	For adequate testing, was reporting complete?	Data analysis independent of sponsor?
Tshefu 2010	41	0, 3, 7, 282	3, 7, 28	Adequate	Complete	No
Kayentao 2012	41	0, 3, 7, 28, 42	3, 7	Adequate	Incomplete 3	No
Rueangweerayut 2012	41	0, 28, 42	0, “post baseline”	Inadequate	-4	No
Poravuth 2011	41	0, 3, 7, 282	3, 7, 28	Adequate	Complete	Yes
Ringwald 1996	41	0, 7	0, 7	Inadequate	—	Yes
Ringwald 1998	51,5	0, 7	0, 7	Inadequate	—	Yes

¹ Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL).

² Plus day 42 if clinically indicated.

³ Does not report the outcome data for day 28 in additional file 3.

⁴ The trial did not report ALP values for all participants (ALT and AST values for 848 patients in the artesunate pyronaridine arm and for 423 participants in the artesunate mefloquine arm at baseline; AST values only for 635 participants and 308 participants respectively at baseline).

⁵ Plus conjugated bilirubin in addition.